Studies: Amgen’s new osteoporosis drug cuts fracture risk

Thursday is a big day for Amgen Inc., as company officials will be in Washington meeting with a Food and Drug Administration advisory panel to discuss their licensing application for a new drug that’s critical to the company’s future success. So it came as welcome news for the Thousand Oaks-based drug manufacturer to see positive findings published today in The New England Journal of Medicine For the full story click here